These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 8837987)

  • 21. Impaired pantomime in schizophrenia: association with frontal lobe function.
    Walther S; Vanbellingen T; Müri R; Strik W; Bohlhalter S
    Cortex; 2013 Feb; 49(2):520-7. PubMed ID: 22264446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Change in "overinclusive" thinking of schizophrenic patients is related to plasma phenothiazine concentration.
    Phillipson OT; Baker J; Williams M
    Adv Biochem Psychopharmacol; 1980; 24():591-7. PubMed ID: 6105805
    [No Abstract]   [Full Text] [Related]  

  • 23. Change in quantified electroencephalography (QEEG) with medication and altered clinical state in the same subjects with schizophrenia.
    Harris A; Gordon E; Anderson J; Ritchie G; McLachlan C; Meares R
    Schizophr Res; 1997 Jan; 23(1):87-9. PubMed ID: 9050132
    [No Abstract]   [Full Text] [Related]  

  • 24. Executive functioning component mechanisms and schizophrenia.
    Kerns JG; Nuechterlein KH; Braver TS; Barch DM
    Biol Psychiatry; 2008 Jul; 64(1):26-33. PubMed ID: 18549874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol.
    Gallhofer B; Jaanson P; Mittoux A; Tanghøj P; Lis S; Krieger S
    Pharmacopsychiatry; 2007 Nov; 40(6):275-86. PubMed ID: 18030652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study.
    Krivoy A; Weizman A; Laor L; Hellinger N; Zemishlany Z; Fischel T
    Eur Neuropsychopharmacol; 2008 Feb; 18(2):117-21. PubMed ID: 17728110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Electroencephalography in schizophrenic patients: comparison between neuroleptic-naive state and after treatment.
    Nagase Y; Okubo Y; Toru M
    Biol Psychiatry; 1996 Sep; 40(6):452-6. PubMed ID: 8879464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of schizophrenia negative symptoms: future prospects.
    Erhart SM; Marder SR; Carpenter WT
    Schizophr Bull; 2006 Apr; 32(2):234-7. PubMed ID: 16492797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypofrontality in schizophrenic patients and its relevance for the choice of antipsychotic medication: an event-related potential study.
    Ehlis AC; Pauli P; Herrmann MJ; Plichta MM; Zielasek J; Pfuhlmann B; Stöber G; Ringel T; Jabs B; Fallgatter AJ
    World J Biol Psychiatry; 2012 Mar; 13(3):188-99. PubMed ID: 21517702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between frontal N-acetylaspartate and cognitive deficits in first-episode schizophrenia.
    Galińska B; Szulc A; Tarasów E; Kubas B; Dzienis W; Siergiejczyk L; Czernikiewicz A; Walecki J
    Med Sci Monit; 2007 May; 13 Suppl 1():11-6. PubMed ID: 17507879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of subjective well-being in schizophrenic patients with gait parameters, expert-rated motor disturbances, and psychopathological status.
    Putzhammer A; Perfahl M; Pfeiff L; Hajak G
    Pharmacopsychiatry; 2005 May; 38(3):132-8. PubMed ID: 15902585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent and remote memory dissociation: medication effects and hippocampal function in schizophrenia.
    Gilbertson MW; van Kammen DP
    Biol Psychiatry; 1997 Oct; 42(7):585-95. PubMed ID: 9376455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Deficit schizophrenias].
    Puech AJ
    Encephale; 1996 Jun; 22 Spec No 2():1. PubMed ID: 8767033
    [No Abstract]   [Full Text] [Related]  

  • 34. Relationship between residual symptomatology and auditory evoked potentials in schizophrenic outpatients.
    Hegerl U; Gaebel W; Ulrich G
    Pharmacopsychiatry; 1988 Nov; 21(6):329-30. PubMed ID: 2907638
    [No Abstract]   [Full Text] [Related]  

  • 35. Experience with a drug-free month in schizophrenic outpatients.
    Heinrichs DW; Carpenter WT
    Psychopharmacol Bull; 1985; 21(1):117-9. PubMed ID: 2858904
    [No Abstract]   [Full Text] [Related]  

  • 36. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients.
    Feifel D; Macdonald K; Nguyen A; Cobb P; Warlan H; Galangue B; Minassian A; Becker O; Cooper J; Perry W; Lefebvre M; Gonzales J; Hadley A
    Biol Psychiatry; 2010 Oct; 68(7):678-80. PubMed ID: 20615494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Schizophrenic syndromes and frontal lobe performance.
    Liddle PF; Morris DL
    Br J Psychiatry; 1991 Mar; 158():340-5. PubMed ID: 2036532
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frontal lobe function and social adjustment in patients with schizophrenia: near-infrared spectroscopy.
    Watanabe Y; Urakami T; Hongo S; Ohtsubo T
    Hum Psychopharmacol; 2015 Jan; 30(1):28-41. PubMed ID: 25408137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial and developmental abnormalities of front lobe function and neurochemistry in schizophrenia.
    Deakin FW; Simpson MD; Slater P; Hellewell JS
    J Psychopharmacol; 1997; 11(2):133-42. PubMed ID: 9254279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preliminary trial of clonidine treatment in two patients suffering from chronic schizophrenia.
    Elizur A; Levy A; Lahav M; Blum I
    Commun Psychopharmacol; 1980; 4(6):507-17. PubMed ID: 6117398
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.